Pfizer Inc. (PFE)
| Market Cap | 146.78B |
| Revenue (ttm) | 63.63B |
| Net Income (ttm) | 8.03B |
| Shares Out | 5.67B |
| EPS (ttm) | 1.41 |
| PE Ratio | 18.34 |
| Forward PE | 8.77 |
| Dividend | $1.72 (6.64%) |
| Ex-Dividend Date | Jan 24, 2025 |
| Volume | 31,794,329 |
| Open | 25.86 |
| Previous Close | 25.89 |
| Day's Range | 25.75 - 26.09 |
| 52-Week Range | 24.48 - 31.54 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 31.92 (+23.24%) |
| Earnings Date | Feb 4, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 8.77% compared to the previous year's $58.50 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $31.92, which is an increase of 23.24% from the latest price.
News
Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports
Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.
Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends
The S&P 500 is up 3.96% YTD, and I predict it could reach 7,000 by the end of 2025. The Dividend Harvesting Portfolio reached a new milestone with a 28.65% ROI, generating $2,010.09 in forward annuali...
10 Ideal 'Safer' January Dividend Buys, Out Of 40 Choices From Readers
Before January 31, 2025, my REaders mentioned 40 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about the ReFa/Ro. ...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Why Pfizer's Stock Price Isn't Reflecting Its True Value
Pfizer's EPS and revenue beat my expectations, mainly due to strong sales of its anti-cancer medications. So, Xtandi sales amounted to $565 million in the fourth quarter of 2024, an increase of 79.9% ...
Pfizer CEO Albert Bourla: Focusing on opportunities outside of vaccines with RFK Jr.
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.
Pfizer: Danuglipron Could Tip The Scale In A Few Years, But For Now, Sell
I rate Pfizer a sell for the next 18–24 months. I expect continued headwinds from Medicare Part D redesign and patent expirations for Eliquis and Prevnar-13 in 2026. Medicare changes will cut $1 billi...
Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
The Big 3: AMSC, PFE, GOLD
Alan Knuckman turns to stocks he believes aren't as renowned as their peers. He explains why he's watching American Superconductor (ASMC), Pfizer (PFE), and Barrick Gold (GOLD) for today's Big 3.
Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in...
U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (br...
Pfizer: 3 Key Risks That Warrant A Sell
Pfizer's business is facing material revenue shrink issues due to many patent expirations over the next 3 years. Quarterly revenue run rate analysis suggests management may be underestimating the impa...
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today its latest ...
Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up results from the Phas...
A Historic Opportunity To Win Big With Dividend Stocks
The current market offers a historic opportunity for dividend stocks. We detail why this is a historic opportunity for dividend investors. We also discuss some of the names that we are buying to take ...
Pfizer: Challenges Loom Amid Overvaluation
I have downgraded Pfizer Inc. stock to Strong Sell due to stagnant revenue, substantial patent cliffs, regulatory, legal, and reputational headwinds, and overvaluation concerns. Despite a 24.7% YoY re...
Fighting Cancer Becomes Top Priority for Pfizer
Pfizer chairman and CEO Albert Bourla sees cancer as Pfizer's next big chance to save the world. The complexity of cancers makes treatments expensive to develop and challenging to customize, but the a...
Income Strategy: I'm Stashing Cash Into These Wonderful Dividends
Inflation can be countered by investing in income-generating assets like consumer staples, energy, and pharmaceuticals, which provide essential products and reliable dividends. In this article, I high...
These S&P 500 Stocks Yield 6%. They Could Be Better Than Bonds.
Investors looking for yield shouldn't forget dividend stocks.
Should You Pick PFE Stock At $25?
Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per s...
MoneyShow's Best Investment Ideas For 2025: Part 9
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with tur...
Pfizer, Inc. (PFE) Q4 2024 Earnings Call Transcript
Pfizer, Inc. (NYSE:PFE) Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ET Company Participants Francesca DeMartino - Senior Vice President, Chief Investor Relations Officer Albert Bourla ...
Nasdaq Surges Over 1%; Pfizer Earnings Top Estimates
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.
Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job
Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vot...